These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Human muscle acetylcholine receptor reactive T and B lymphocytes in myasthenia gravis. Yi Q; Lefvert AK Ann N Y Acad Sci; 1993 Jun; 681():339-41. PubMed ID: 8357186 [No Abstract] [Full Text] [Related]
44. Possible strategies for the treatment of myasthenia gravis and other autoimmune diseases. Nossal GJ Ann N Y Acad Sci; 1987; 505():610-8. PubMed ID: 3500669 [No Abstract] [Full Text] [Related]
45. Therapies for exacerbation of myasthenia gravis. The mechanism of action of intravenous high-dose immunoglobulin G. Ferrero B; Durelli L; Cavallo R; Dutto A; Aimo G; Pecchio F; Bergamasco B Ann N Y Acad Sci; 1993 Jun; 681():563-6. PubMed ID: 8357198 [No Abstract] [Full Text] [Related]
46. [Myasthenia gravis and antiacetylcholine receptor antibody (author's transl)]. Ota M; Hayashi K Horumon To Rinsho; 1979 Aug; 27(8):833-42. PubMed ID: 385178 [No Abstract] [Full Text] [Related]
47. Sharing of epitopes by bacteria and the nicotinic acetylcholine receptor: a possible role in the pathogenesis of myasthenia gravis. Stefansson K; Dieperink ME; Richman DP; Marton LS Ann N Y Acad Sci; 1987; 505():451-60. PubMed ID: 2446557 [No Abstract] [Full Text] [Related]
48. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column]. Yeh JH; Chiu HC J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565 [TBL] [Abstract][Full Text] [Related]
49. Immunoadsorption plasmapheresis for severe generalised myasthenia gravis. Ichikawa M; Koh CS; Hata Y; Tohyama M; Tsuno T; Komiyama A Arch Dis Child; 1993 Aug; 69(2):236-8. PubMed ID: 8215529 [TBL] [Abstract][Full Text] [Related]
50. Absence of acetylcholine receptor antibody in relatives of myasthenic patients. Walker GL; Nicholson LV; Mastaglia FL Lancet; 1980 Apr; 1(8171):778-9. PubMed ID: 6103204 [No Abstract] [Full Text] [Related]
51. Reaction of myasthenic antibodies with heart & brain nicotinic acetylcholine receptors. Asthana D; Jaffery NF; Kumar R; Ahuja GK; Jailkhani BL Indian J Med Res; 1987 Oct; 86():493-9. PubMed ID: 3127338 [No Abstract] [Full Text] [Related]
52. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Protti MP; Manfredi AA; Horton RM; Bellone M; Conti-Tronconi BM Immunol Today; 1993 Jul; 14(7):363-8. PubMed ID: 8363727 [TBL] [Abstract][Full Text] [Related]
53. Specific suppression of the antibody response to acetylcholine receptor in vitro and in vivo by daunomycin-acetylcholine receptor conjugates. Shelton D; Fujii Y; Knogge W; Lindstrom J Ann N Y Acad Sci; 1988; 540():530-2. PubMed ID: 3207284 [No Abstract] [Full Text] [Related]
54. The role of acetylcholine receptor antibodies in myasthenia gravis. Appel SH; Elias SB; Chauvin P Fed Proc; 1979 Sep; 38(10):2381-5. PubMed ID: 478014 [TBL] [Abstract][Full Text] [Related]
55. Myasthenia gravis and lymphoblastic lymphoma antiacetylcholine receptor antibody as a tumor marker--a case report. Mortimer JE; Kidd P Cancer Invest; 1989; 7(4):327-31. PubMed ID: 2686813 [TBL] [Abstract][Full Text] [Related]
59. Antigen-specific therapy of experimental myasthenia gravis with acetylcholine receptor-gelonin conjugates in vivo. Urbatsch IL; Sterz RK; Peper K; Trommer WE Eur J Immunol; 1993 Mar; 23(3):776-9. PubMed ID: 8449224 [TBL] [Abstract][Full Text] [Related]
60. Time course of improved neuromuscular function following plasma exchange alone and plasma exchange with prednisone/azathioprine in myasthenia gravis. Milner-Brown HS; Miller RG J Neurol Sci; 1982 Dec; 57(2-3):357-68. PubMed ID: 6298372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]